NovaBridge Biosciences
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NovaBridge Biosciences, a global biotechnology platform, has recently undergone a significant corporate transformation, transitioning from its former identity as I-Mab. The company, trading under the new ticker NBP since October 30, 2025, is dedicated to advancing transformative medicines primarily in immuno-oncology and ophthalmic diseases. Its differentiated pipeline includes givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, now preparing for a global randomized Phase 2 clinical study in gastric cancer slated for early 2026. Uliledlimab, a CD73 antibody, is currently in Phase 2 development for various solid tumors. Additionally, ragistomig, an anti-PD-L1 x 4-1BB bispecific antibody, is progressing through Phase 1b clinical trials for solid tumors. A key addition to its portfolio is VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG-2, which is being developed by its newly established subsidiary, Visara, Inc., for ophthalmic indications such as wet age-related macular degeneration and diabetic macular edema, with Phase 3 readiness anticipated in 2026. This strategic shift embraces a "hub-and-spoke" operational model to accelerate asset development and optimize risk management, alongside plans for a dual listing on both NASDAQ and the Hong Kong Stock Exchange to enhance global capital access. NovaBridge Biosciences maintains strategic alliances, including collaborations with ABL Bio for bispecific antibodies and Bristol Myers Squibb for givastomig development. Established in 2014, the company's headquarters are located in Rockville, Maryland.
Company News
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
Reviewing I-Mab (NASDAQ:NBP) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO)
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
NovaBridge Biosciences to Participate in September Investor Conferences
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
Woodside Energy Second Quarter Report for Period Ended 30 June 2026
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
I-Mab (NASDAQ:NBP) Trading Down 4.9% – Time to Sell?
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
NovaBridge's Givastomig Could Drive A Major Re-Rating
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update